ArticleCureus2026
Anticoagulation Monitoring in Recurrent Venous Thromboembolism Associated With Antiphospholipid Antibodies and Subsequent Heparin-Induced Thrombocytopenia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A woman in her 20s with class III obesity and strongly positive antiphospholipid antibodies developed phlegmasia cerulea dolens and a new pulmonary embolus after recent catheter-directed thrombolysis. Before the first documented heparin administration, activated partial thromboplastin time was 95.5 s and international normalized ratio was 1.5. Eight subsequent paired samples showed activated partial thromboplastin times of 176 s to over 200 s with heparin anti-Xa activity of 0.20-0.66 IU/mL. Lupus anticoagulant testing was uninterpretable during anticoagulation, and international normalized ratio reliability was not independently established. Later thrombocytopenia prompted repeat heparin-induced thrombocytopenia testing despite an earlier negative result; a strongly positive immunoassay supported the treating team's diagnosis and transition to fondaparinux. This case illustrates the importance of selecting appropriate anticoagulation monitoring from the outset and reassessing heparin-induced thrombocytopenia when the clinical picture changes. Whether assay interference contributed to recurrent thrombosis remains unresolved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.